Skip to content
Menu

Definium Therapeutics, Inc. DFTX

Full chart Compare
Set alert

Price alert · DFTX

All alert types
28.73 USD -0.75 (-2.54%)

As ofNov 20, 2026, 3:00 PM EST

28.44 Day range 29.51
10.47 52-week range 49.70
YTD
+114.56%
1 year
+164.06%

5D -3.44 (-10.71%)

3032MonTueWedThuFri28.68
Market cap
3.93B
EPS (ttm)
-2.92
Shares out
136.90M
Forward P/E
-15.55
YTD return
+114.56%
1-year return
+164.06%
50-day average
35.56
200-day average
30.61
Enterprise value
2.98B
Price / book
4.17
Volume
2.36M
Avg volume
1.98M
Open
28.83
Previous close
29.48
Day's range
28.44 – 29.51
52-week range
10.47 – 49.70
Beta
2.21
Analysts
Strong Buy
Price target
72.83 (+153.5%)
Earnings date
Feb 25, 2027

Key statistics

Free cash flow
-118.64M
Total cash
1.05B
Total debt
36.66M
Return on equity
-61.44%
Short % of float
7.07%

Fundamental scorecard

3 of 25 checks passed on DFTX’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
DFTX Revenue — quarterly 0
DFTX Net income — quarterly -50.96M
DFTX EPS — quarterly -0.37

Earnings

DFTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.51———
Nov 9, 2026Sep 30, 2026-0.56294-0.46+0.10+18.29%
Aug 6, 2026Jun 30, 2026-0.54102-1.44-0.90-166.16%
May 7, 2026Mar 31, 2026-0.47-0.71-0.24-51.06%
Feb 26, 2026Dec 31, 2025-0.48368-0.51-0.03-5.44%
Nov 6, 2025Sep 30, 2025-0.52-0.78-0.26-50.00%

Upgrades / downgrades

DFTX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 17, 2026JP MorganmainOverweightOverweight
Nov 10, 2026RBC CapitalmainOutperformOutperform
Oct 9, 2026JP Morganinit—Overweight
Sep 15, 2026Canaccord GenuitymainBuyBuy
Sep 15, 2026BairdmainOutperformOutperform
Sep 14, 2026HC Wainwright & Co.reitBuyBuy

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on DFTX — it syncs with the Stock Master app.

Insider holders

DFTX insider holders
InsiderRelationLatest transactionDateShares held
BARROW ROBERT BChief Executive OfficerSaleSep 24, 20262,213,090
BRUHN SUZANNE LOUISEDirectorStock Award(Grant)Jun 10, 202624,289
CRYSTAL ROGERDirectorStock Award(Grant)Jun 10, 202624,289
GRYSKA DAVID WDirectorStock Award(Grant)Jun 10, 202619,900
KARLIN DANIEL ROLLINGSOfficer and DirectorSaleSep 24, 2026792,846
KREBS ANDREASDirectorStock Award(Grant)Jun 10, 202619,773

Institution ownership

DFTX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.60%11,772,595347.06MSep 29, 2026
FMR, LLC6.63%9,082,203267.74MSep 29, 2026
Capital World Investors6.03%8,255,584243.37MSep 29, 2026
Janus Henderson Group Ltd.5.26%7,196,316212.15MSep 29, 2026
Avoro Capital Advisors LLC5.15%7,050,000207.83MSep 29, 2026
Driehaus Capital Management, LLC4.96%6,788,022200.11MSep 29, 2026

Fund ownership

DFTX fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc7.49%10,253,153302.26MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.37%3,243,23395.61MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.09%1,486,83243.83MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.04%1,424,92942.01MAug 30, 2026
T. Rowe Price Health Sciences Fund, Inc.0.94%1,287,31837.95MJun 29, 2026
iShares Trust-iShares Russell 2000 Growth ETF0.86%1,170,71334.51MSep 29, 2026